8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 7, 2026·SEC
Supernus Pharmaceuticals, Inc.(SUPN)Earnings, Financials & Key Ratios
SUPN•NASDAQ
$47.41
Price updated Jul 7, 2026
AboutSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.Show more
- Revenue$719M+8.6%
- EBITDA$55M-66.3%
- Net Income-$39M-152.2%
- EPS (Diluted)-0.68-151.5%
- Gross Margin89.63%+1.6%
- EBITDA Margin7.61%-68.9%
- Operating Margin-5.13%-141.6%
- Net Margin-5.36%-148.0%
- ROE-3.68%-148.7%
SUPN Price & Volume
Supernus Pharmaceuticals, Inc. (SUPN) stock price & volume — 10-year historical chart
Loading chart...
CNS Portfolio Transition Drives Volatile Financial Performance
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory and generic erosion
Key Thesis Takeaways
- Supernus is navigating a complex transition as it attempts to offset the decline of its legacy epilepsy portfolio with high-cost commercialization efforts for its ADHD franchise.
- While the company maintains a robust balance sheet with minimal leverage, the inconsistent operating income and reliance on non-cash adjustments suggest that long-term profitability remains unproven.
- Investors should monitor whether the 38.6% year-over-year revenue growth in 2026Q1 can be sustained without further eroding operating margins, which reached -31.4% in 2025Q3.
Verdict Logic
while the company maintains a healthy current ratio of 1.96, the lack of consistent profitability and the high $33.1 million stock-based compensation expense in 2025Q4 suggest significant execution risk.
SUPN Growth Metrics
Supernus Pharmaceuticals, Inc. (SUPN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.41%
5 Years6.68%
3 Years2.52%
TTM16.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-146.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-146.09%
Return on Capital
10 Years13.95%
5 Years2.88%
3 Years1.34%
Last Year-3.37%
SUPN Recent Earnings
Supernus Pharmaceuticals, Inc. (SUPN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.59+110.7%
$0.28
Rev
$208M+7.7%
$193M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.92+228.6%
$0.28
Rev
$212M+8.4%
$195M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.01+23.2%
$0.82
Rev
$192M-1.3%
$195M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.91+93.6%
$0.47
Rev
$165M-1.7%
$168M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.59vs $0.28+110.7% | $208Mvs $193M+7.7% |
| Q1 2026 | Feb 24, 2026 | $0.92vs $0.28+228.6% | $212Mvs $195M+8.4% |
| Q4 2025 | Nov 4, 2025 | $1.01vs $0.82+23.2% | $192Mvs $195M-1.3% |
| Q3 2025 | Aug 5, 2025 | $0.91vs $0.47+93.6% | $165Mvs $168M-1.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Supernus Pharmaceuticals, Inc. (SUPN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $47.41 | $2.73B | -69.72 | 8.63% | -5.36% | -3.68% | — | |
| $25.82 | $1.02B | 161.38 | 3.63% | 1.27% | 1.31% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — |
Compare SUPN vs Peers
Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SUPN SEC Filings & Documents
Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SUPN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SUPN Frequently Asked Questions
Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Supernus Pharmaceuticals, Inc.'s revenue?
Supernus Pharmaceuticals, Inc. (SUPN) reported $776.8M in revenue for fiscal year 2025. This represents a 8639% increase from $8.9M in 2008.
How fast is Supernus Pharmaceuticals, Inc. growing?
Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 8.6% over the past year. This is steady growth.
Is SUPN profitable?
Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $29.0M for fiscal year 2025.
Dividend & Returns
What is SUPN's return on equity?
Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.
What is Supernus Pharmaceuticals, Inc.'s free cash flow?
Supernus Pharmaceuticals, Inc. (SUPN) generated $82.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.